253 related articles for article (PubMed ID: 34737296)
1. Restoration of HBV-specific CD8
Wang D; Fu B; Shen X; Guo C; Liu Y; Zhang J; Sun R; Ye Y; Li J; Tian Z; Wei H
Signal Transduct Target Ther; 2021 Nov; 6(1):376. PubMed ID: 34737296
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
[TBL] [Abstract][Full Text] [Related]
3. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
4. [Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):583-588. PubMed ID: 29056007
[No Abstract] [Full Text] [Related]
5. The reduction in CD8
Liu R; Chen Y; Guo J; Li M; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Zhang H; Xie Y
BMC Infect Dis; 2020 Aug; 20(1):590. PubMed ID: 32778058
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
8. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
10. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
[No Abstract] [Full Text] [Related]
11. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B.
Chen J; Wang Y; Wu XJ; Li J; Hou FQ; Wang GQ
World J Gastroenterol; 2010 Dec; 16(48):6145-50. PubMed ID: 21182232
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Sherman AC; Trehanpati N; Daucher M; Davey RT; Masur H; Sarin SK; Kottilil S; Kohli A
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):665-72. PubMed ID: 23259453
[TBL] [Abstract][Full Text] [Related]
14. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.
Park JJ; Wong DK; Wahed AS; Lee WM; Feld JJ; Terrault N; Khalili M; Sterling RK; Kowdley KV; Bzowej N; Lau DT; Kim WR; Smith C; Carithers RL; Torrey KW; Keith JW; Levine DL; Traum D; Ho S; Valiga ME; Johnson GS; Doo E; Lok AS; Chang KM;
Gastroenterology; 2016 Mar; 150(3):684-695.e5. PubMed ID: 26684441
[TBL] [Abstract][Full Text] [Related]
16. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study.
Liu YH; Wu T; Sun N; Wang GL; Yuan JZ; Dai YR; Zhou XH
J Huazhong Univ Sci Technolog Med Sci; 2014 Aug; 34(4):542-547. PubMed ID: 25135724
[TBL] [Abstract][Full Text] [Related]
18. Frequency of T-cell FoxP3⁺ Treg and CD4⁺/CD8⁺ PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon.
Ma H; Zhang HH; Wei L
Chin Med J (Engl); 2013 Jan; 126(2):267-73. PubMed ID: 23324275
[TBL] [Abstract][Full Text] [Related]
19. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
